Hypertension Drugs Market Size & Share, by Drug Class (Alpha & Beta Blockers, Diuretics, Angiotensin Converting Enzyme Inhibitors, Angiotensin II Receptor Blockers, Renin Inhibitors); Type (Systemic, Pulmonary); Distribution Channel (Hospitals, Clinics, Research Laboratories, Retail Pharmacies) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2023-2035

  • Report ID: 2845
  • Published Date: Jul 27, 2023
  • Report Format: PDF, PPT

Global Market Size, Forecast, and Trend Highlights Over 2023-2035

Hypertension Drugs Market size is poised to reach USD 40 Billion by the end of 2035, growing at a CAGR of 4% during the forecast period, i.e., 2023-2035. In the year 2022, the industry size of hypertension drugs was USD 20 Billion. The market is expanding due to an increase in hypertension cases around the world, as it is a condition caused by chronic kidney infection, apnea, and other factors, and is the most common health disorder among the majority of the global population. As a result, the high demand for hypertension drugs is attributed to the high sales volume of hypertension drugs and their available treatment options.

The growing prevalence of insomnia across the globe is believed to fuel market growth. For instance, insomnia is a common sleep disorder that makes it difficult to fall asleep or sometimes causes a person to wake up early. Insomnia is noticed to be interlinked with hypertension and beta-blockers are highly used to treat insomnia heavily across the globe. For instance, it was stated that in every 3 adults across the globe, one of them has insomnia.

Hypertension Drugs Market
Get more information on this report: Request Free Sample PDF

Hypertension Drugs Sector: Growth Drivers and Challenges

Growth Drivers

  • Increasing Prevalence of Renal Disease- renal disease is a medical condition in which kidneys are damaged and lose their capability to filter blood causing severe health problems such as hypertension is one of them. For instance, around 800 million people across the globe are observed to be living with some sort of renal disease.
  • Rising Trend of Work from Home (WFH) – work from home is a process that involves less mobility that can cause strain in arteries carrying blood. Hence, working from home is noticed to be one of the major reasons. Around 80% of the employees were observed to prefer working from home while by the year 2025, around 35 million Americans will be working remotely.
  • Growing Consumption of Tobacco and Cigarette- smoking habits and tobacco consumption can be one of the major causes of hypertension since it was noticed to increase blood pressure and masked hypertension. For instance, it was estimated that around 8 million people die annually owing to the consumption of tobacco.


  • Rising Number of Alternate Generic Drugs- There is an increase in the number of generic drugs and other substitutes associated with the treatment of hypertension which negatively affects the market growth. Further, the presence of some side effects of these drugs is estimated to hinder the growth of the global hypertension drugs market during the forecast period.
  • Possibilities of Side-Effect such as Dizziness and Headaches
  • Higher Cost Associated with Hypertension Drugs

Hypertension Drugs Market: Key Insights

Base Year


Forecast Year




Base Year Market Size (2022)

~ USD 20 Billion

Forecast Year Market Size (2035)

~ USD 40 Billion

Regional Scope

  • North America (U.S., and Canada)
  • Latin America (Mexico, Argentina, Rest of Latin America)
  • Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific)
  • Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)
Get more information on this report: Request Free Sample PDF

Hypertension Drugs Segmentation

Drug Class (Alpha & Beta Blockers, Diuretics, Angiotensin Converting Enzyme Inhibitors, Angiotensin II Receptor Blockers, Renin Inhibitors)

The diuretics segment is estimated to gain a robust market share of 48% in the coming years owing to its high preference among the majority of patients for hypertension treatment. Diuretics, sometimes known as water pills, help the body get rid of surplus fluids and are frequently tried as the first drug for hypertension.  They are preferred by patients owing to their effectiveness, inexpensive price, and few adverse effects. For instance, Chlorthalidone is one of the most often prescribed thiazide diuretics, which has been FDA-approved since 1960. Further, studies have shown that 1 in every 3 adults having hypertension was reported to take diuretics, which is anticipated to drive the growth of the diuretics segment during the forecast period.

Type (Systemic, Pulmonary)

The pulmonary segment in the hypertension drugs market is set to garner a notable share in the near future. Pulmonary hypertension is described as high blood pressure in the blood vessels that are responsible for supplying blood to pulmonary arteries. Pulmonary disease can be life-threatening since it can damage the right side of the heart. For instance, around 500 to 100 new cases of pulmonary arterial hypertension are diagnosed in the United States every year which sums up to nearly 12 cases per million people.

Furthermore, the systemic segment is also anticipated to hold a significant share of the hypertension drug market during the forecast period. Systemic hypertension is also another form of high blood pressure in arteries carrying blood from the heart to the body.

Our in-depth analysis of the global market includes the following segments:

           Drug Class

  • Alpha & Beta Blockers
  • Diuretics
  • Angiotensin Converting Enzyme Inhibitors
  • Angiotensin II Receptor Blockers
  • Renin Inhibitors


  • Systemic
  • Pulmonary

            Distribution Channel

  • Hospitals
  • Clinics
  • Research Laboratories
  • Retail Pharmacies

Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.

Customize this Report

Hypertension Drugs Industry - Regional Synopsis

North American Market Forecast

Hypertension drugs market in North America is predicted to account for the largest share of 30% by 2035, impelled by the presence of leading market players in the region that manufacture and market hypertension drugs. For instance, the presence of leading market players may result in the development of innovative drugs for hypertension and improved treatment options for patients in the region.

APAC Market Statistics

The APAC hypertension drugs market is estimated to be the second largest, during the forecast timeframe led by the rise in the geriatric population, especially in countries such as China, India, and Japan. The elderly population is more prone to chronic conditions such as high blood pressure which requires long-term management. This extended treatment period is expected to increase the demand for hypertension drugs in the region. According to the World Health Organization (WHO), owing to rising life expectancy and falling birth rates, 28% of China's population is expected to be over 60 by 2040.

Research Nester
Hypertension Drugs Market Size
Get more information on this report: Request Free Sample PDF

Companies Dominating the Hypertension Drugs Landscape

    • Janssen Global Services, LLC
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Atnahs Pharma UK Limited
    • Sanofi US Services Inc.
    • Pfizer Laboratories Div Pfizer Inc
    • Merck & Co., Inc.
    • Abbott Laboratories
    • Daiichi Sankyo Company, Limited
    • Novartis Pharmaceuticals Corporation
    • Boehringer Ingelheim group
    • Lupin Ltd.


In The News

  • Janssen Global Services, LLC announced that it has submitted an approval request to the U.S. Food and Drug Administration (FDA) for OPSUMIT (macitentan) for treating adults with inoperable chronic thromboembolic pulmonary hypertension (CTEPH, WHO Group 4)
  • AstraZeneca announced that it has completed the divestment agreement of its established hypertension medicines with Atnahs Pharma UK Limited.

Author Credits:  Radhika Gupta, Shivam Bhutani

  • Report ID: 2845
  • Published Date: Jul 27, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Increasing cases of hypertension around the world and the growing prevalence of insomnia across the globe are the major factors driving the growth of the market.

The market size of Hypertension Drugs is anticipated to attain a CAGR of 4% over the forecast period, i.e., 2023-2035.

The major players in the market are Atnahs Pharma UK Limited, Sanofi US Services Inc., Pfizer Laboratories Div Pfizer Inc, Merck & Co., Inc., Abbott Laboratories, Daiichi Sankyo Company, Limited, and others.

The diuretics segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.

The market in the North America region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.
Hypertension Drugs Market Report Scope

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying